In marked contrast, no tumors or lesions were found in Sphk2-KO mice (Fig. 1J), defining a requirement for SphK2 in NAFLD-HCC development in vivo. The gene discussed is SPHK2; the disease is metabolic dysfunction-associated steatotic liver disease.